{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:56:33Z","timestamp":1792875393294,"version":"4.5.0"},"reference-count":323,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Glaucoma, a leading cause of irreversible blindness, represents a significant challenge in ophthalmology. This review examines recent advancements in glaucoma treatment, focusing on innovative medications and creative strategies. While new agents offer promising methods for lowering intraocular pressure (IOP), they also pose challenges related to efficacy and side effects. Alongside IOP reduction, emerging neuroprotective approaches are being explored to safeguard retinal ganglion cells (RGCs) from glaucoma-induced damage. The review also evaluates the potential of novel drug delivery systems, such as biodegradable implants and nanoparticles, to enhance treatment effectiveness and patient adherence. Additionally, it highlights the role of personalized medicine in identifying new biomarkers and customizing therapies based on individual genetic and environmental factors.<\/jats:p>","DOI":"10.3389\/fmed.2025.1527319","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T05:00:21Z","timestamp":1742965221000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Challenging glaucoma with emerging therapies: an overview of advancements against the silent thief of sight"],"prefix":"10.3389","volume":"12","author":[{"given":"Solange","family":"Sarkis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Chamard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Daien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Michon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"Weinreb","year":"2014","journal-title":"JAMA."},{"key":"B2","volume-title":"Acute Angle-Closure Glaucoma. StatPearls, Treasure Island (FL): StatPearls Publishing.","author":"Khazaeni","year":"2024"},{"key":"B3","first-page":"668","article-title":"Glaucoma","volume":"93","author":"Gupta","year":"2016","journal-title":"Am Fam Physician."},{"key":"B4","volume-title":"Normal Tension Glaucoma.","author":"Gosling","year":"2023"},{"key":"B5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S0002-9394(01)00964-3","article-title":"Risk factors for progression of visual field abnormalities in normal-tension glaucoma","volume":"131","author":"Drance","year":"2001","journal-title":"Am J Ophthalmol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0161-6420(97)30112-2","article-title":"Biometry and primary angle-closure glaucoma among Chinese, white, and black populations","volume":"104","author":"Congdon","year":"1997","journal-title":"Ophthalmology."},{"key":"B7","volume-title":"Glaucoma","author":"Dietze","year":"2023"},{"key":"B8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.5005\/jp-journals-10028-1226","article-title":"Steroid-induced glaucoma: an avoidable irreversible blindness","volume":"11","author":"Phulke","year":"2017","journal-title":"J Curr Glaucoma Pract."},{"key":"B9","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.survophthal.2020.01.002","article-title":"Steroid-induced glaucoma: Epidemiology, pathophysiology, and clinical management","volume":"65","author":"Roberti","year":"2020","journal-title":"Surv Ophthalmol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"5707","DOI":"10.18410\/jebmh\/2017\/1146","article-title":"MRA clinical study of pseudoexfoliation in a tertiary eye care centre","volume":"4","author":"Palagani","year":"2017","journal-title":"J Evid Based Med Healthc."},{"key":"B11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2147\/OPTH.S181444","article-title":"Monitoring and management of the patient with pseudoexfoliation syndrome: current perspectives","volume":"13","author":"Tekin","year":"2019","journal-title":"Clin Ophthalmol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2147\/OPTO.S321716","article-title":"Pseudoexfoliation syndrome and associated factors among adults at gondar university comprehensive specialized hospital tertiary eye care and training center: a cross-sectional study","volume":"13","author":"Yibekal","year":"2021","journal-title":"Clin Optom."},{"key":"B13","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.4103\/0301-4738.73695","article-title":"Normal-tension glaucoma (Low-tension glaucoma)","volume":"59","author":"Anderson","year":"2011","journal-title":"Indian J Ophthalmol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"308505","DOI":"10.1155\/2015\/308505","article-title":"Ocular blood flow and normal tension glaucoma","volume":"2015","author":"Fan","year":"2015","journal-title":"BioMed Res Int."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","article-title":"The relationship between control of intraocular pressure and visual field deterioration","volume":"130","year":"2000","journal-title":"Am J Ophthalmol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch Ophthalmol Chic Ill."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/6138132","article-title":"Current medical therapy and future trends in the management of glaucoma treatment","volume":"2020","author":"Cvenkel","year":"2020","journal-title":"J Ophthalmol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40123-019-00222-z","article-title":"Open-angle glaucoma: burden of illness, current therapies, and the management of nocturnal IOP variation","volume":"9","author":"Sheybani","year":"2019","journal-title":"Ophthalmol Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1136\/bjophthalmol-2021-319379","article-title":"Direct selective laser trabeculoplasty in open angle glaucoma study design: a multicentre, randomised, controlled, investigator-masked trial (GLAUrious)","volume":"107","author":"Congdon","year":"2023","journal-title":"Br J Ophthalmol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3390\/bioengineering10091096","article-title":"Recent advancements in glaucoma surgery\u2014a review","volume":"10","author":"Ang","year":"2023","journal-title":"Bioengineering."},{"key":"B23","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/APO.0000000000000561","article-title":"Minimally invasive glaucoma surgery in primary angle-closure glaucoma","volume":"11","author":"Song","year":"2022","journal-title":"Asia-Pac J Ophthalmol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3390\/jcm12030828","article-title":"Advances in glaucoma surgery","volume":"12","author":"Mercieca","year":"2023","journal-title":"J Clin Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ajpath.2014.10.023","article-title":"RhoA GTPase-induced ocular hypertension in a rodent model is associated with increased fibrogenic activity in the trabecular meshwork","volume":"185","author":"Pattabiraman","year":"2015","journal-title":"Am J Pathol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1167\/tvst.9.10.27","article-title":"Ripasudil in a model of pigmentary glaucoma","volume":"9","author":"Wang","year":"2020","journal-title":"Transl Vis Sci Technol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2147\/JEP.S281187","article-title":"The latest drugs in development that reduce intraocular pressure in ocular hypertension and glaucoma","volume":"12","author":"Jayanetti","year":"2020","journal-title":"J Exp Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1001\/jamaophthalmol.2013.323","article-title":"Phase 1 clinical trials of a selective rho kinase inhibitor, K-115","volume":"131","author":"Tanihara","year":"2013","journal-title":"JAMA Ophthalmol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.ajo.2013.05.016","article-title":"Phase 2 randomized clinical study of a rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension","volume":"156","author":"Tanihara","year":"2013","journal-title":"Am J Ophthalmol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/IJG.0000000000001203","article-title":"Long-term side effects including blepharitis leading to discontinuation of ripasudil","volume":"28","author":"Saito","year":"2019","journal-title":"J Glaucoma."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1007\/s12325-021-02023-y","article-title":"Long-term intraocular pressure-lowering effects and adverse events of ripasudil in patients with glaucoma or ocular hypertension over 24 months","volume":"39","author":"Tanihara","year":"2022","journal-title":"Adv Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s00417-024-06388-y","article-title":"Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study","volume":"262","author":"Tanihara","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jphs.2024.02.011","article-title":"Drug combination of topical ripasudil and brimonidine enhances neuroprotection in a mouse model of optic nerve injury","volume":"154","author":"Namekata","year":"2024","journal-title":"J Pharmacol Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"10308","DOI":"10.1038\/s41598-020-66928-4","article-title":"Intraocular pressure-lowering effects of ripasudil in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma patients: ROCK-S, a multicentre historical cohort study","volume":"10","author":"Futakuchi","year":"2020","journal-title":"Sci Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7860\/JCDR\/2021\/48878.14851","article-title":"Topical ripasudil as first line treatment for ocular hypertension in uveitis cases: an analytic study","volume":"15","author":"Nagpal","year":"2021","journal-title":"J Clin Diagn Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"5576","DOI":"10.3390\/ijms25115576","article-title":"The application of rho kinase inhibitors in the management of glaucoma","volume":"25","author":"Liu","year":"2024","journal-title":"Int J Mol Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"CD013817","DOI":"10.1002\/14651858.CD013817.pub2","article-title":"Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension","volume":"2022","author":"Freiberg","year":"2022","journal-title":"Cochrane Database Syst Rev."},{"key":"B38","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ajo.2019.06.016","article-title":"Netarsudil\/latanoprost fixed-dose combination for elevated intraocular pressure: three-month data from a randomized phase 3 trial","volume":"207","author":"Asrani","year":"2019","journal-title":"Am J Ophthalmol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/archophthalmol.2007.76","article-title":"Intraocular pressure\u2013lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers","volume":"126","author":"Tanihara","year":"2008","journal-title":"Arch Ophthalmol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1136\/bjophthalmol-2012-302466","article-title":"Ocular hypotensive efficacy, safety and systemic absorption of AR-12286 ophthalmic solution in normal volunteers","volume":"97","author":"Kopczynski","year":"2013","journal-title":"Br J Ophthalmol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1167\/iovs.13-13157","article-title":"AMA0076, a novel, locally acting rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia","volume":"55","author":"Van de Velde","year":"2014","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1167\/iovs.18-25252","article-title":"A highly selective rho-kinase inhibitor (ITRI-E-212) potentially treats glaucoma upon topical administration with low incidence of ocular hyperemia","volume":"60","author":"Hsu","year":"2019","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1167\/iovs.14-14515","article-title":"Nitric oxide (NO): an emerging target for the treatment of glaucoma","volume":"55","author":"Cavet","year":"2014","journal-title":"Investig Opthalmology Vis Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/IJG.0000000000000831","article-title":"Latanoprostene bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: pooled phase 3 study findings","volume":"27","author":"Weinreb","year":"2018","journal-title":"J Glaucoma."},{"key":"B45","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1080\/14656566.2017.1293654","article-title":"Latanoprostene bunod ophthalmic solution 0","volume":"18","author":"Kaufman","year":"2017","journal-title":"Expert Opin Pharmacother."},{"key":"B46","unstructured":"Aerie Pharmaceuticals Receives FDA Approval of Rocklatan for Reduction of IOP"},{"key":"B47","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ogla.2019.03.007","article-title":"Once-daily netarsudil\/latanoprost fixed-dose combination for elevated intraocular pressure in the randomized phase 3 MERCURY-2 study","volume":"2","author":"Walters","year":"2019","journal-title":"Ophthalmol Glaucoma."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.3390\/jcm9123978","article-title":"Cannabinoids in glaucoma patients: the never-ending story","volume":"9","author":"Passani","year":"2020","journal-title":"J Clin Med."},{"key":"B49","year":"2000"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA."},{"key":"B51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1167\/tvst.8.5.15","volume":"8","author":"Taskar","year":"2019","journal-title":"Transl Vis Sci Technol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"959","DOI":"10.2174\/1570159X15666170724104305","article-title":"Neuroprotection by (endo)Cannabinoids in glaucoma and retinal neurodegenerative diseases","volume":"16","author":"Rapino","year":"2018","journal-title":"Curr Neuropharmacol."},{"key":"B53","volume-title":"Cannabis Use for Glaucoma and Associated Pain","author":"Lopez","year":"2024"},{"key":"B54","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.pnpbp.2018.10.002","article-title":"Association between increased retinal background noise and co-occurrent regular cannabis and alcohol use","volume":"89","author":"Lucas","year":"2019","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B55","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.schres.2019.01.013","article-title":"Spatial localization of retinal anomalies in regular cannabis users: the relevance of the multifocal electroretinogram","volume":"219","author":"Schwitzer","year":"2020","journal-title":"Schizophr Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1001\/jamaophthalmol.2016.4761","article-title":"Association between regular cannabis use and ganglion cell dysfunction","volume":"135","author":"Schwitzer","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1159\/000541461","article-title":"Cannabinoids for the treatment of glaucoma: a review","volume":"7","author":"Joshi","year":"2024","journal-title":"Med Cannabis Cannabinoids."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3390\/ph16081149","article-title":"Therapeutic potential of cannabinoids in glaucoma","volume":"16","author":"Lindner","year":"2023","journal-title":"Pharmaceuticals."},{"key":"B59","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.2147\/OPTH.S501494","article-title":"Adverse ocular impact and emerging therapeutic potential of cannabis and cannabinoids: a narrative review","volume":"18","author":"Bondok","year":"2024","journal-title":"Clin Ophthalmol Auckl NZ."},{"key":"B60","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/IJG.0000000000001966","article-title":"Attitudes and perceptions toward the use of medical marijuana by glaucoma specialists","volume":"31","author":"Bergman","year":"2022","journal-title":"J Glaucoma."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1097\/IJG.0000000000002203","article-title":"Public perception of marijuana use for the treatment of glaucoma","volume":"32","author":"Yakobashvili","year":"2023","journal-title":"J Glaucoma."},{"key":"B62","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ogla.2020.06.009","article-title":"Perceptions of marijuana use for glaucoma from patients, cannabis retailers, and glaucoma specialists","volume":"3","author":"Weldy","year":"2020","journal-title":"Ophthalmol Glaucoma."},{"key":"B63","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3389\/fnins.2018.00834","article-title":"The role of endogenous neuroprotective mechanisms in the prevention of retinal ganglion cells degeneration","volume":"12","author":"Pietrucha-Dutczak","year":"2018","journal-title":"Front Neurosci."},{"key":"B64","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jcjo.2018.11.001","article-title":"Medical use of cannabis for glaucoma","volume":"54","author":"Rafuse","year":"2019","journal-title":"Can J Ophthalmol J Can Ophtalmol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/opo.12189","article-title":"Oral treatment with the melatonin agonist agomelatine lowers the intraocular pressure of glaucoma patients","volume":"35","author":"Pescosolido","year":"2015","journal-title":"Ophthalmic Physiol Opt."},{"key":"B66","doi-asserted-by":"publisher","first-page":"100798","DOI":"10.1016\/j.preteyeres.2019.100798","article-title":"Melatonin and the control of intraocular pressure","volume":"75","author":"Alkozi","year":"2020","journal-title":"Prog Retin Eye Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.3390\/ijms24065789","article-title":"Regulation of aqueous humor secretion by melatonin in porcine ciliary epithelium","volume":"24","author":"Li","year":"2023","journal-title":"Int J Mol Sci."},{"key":"B68","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1097\/IJG.0b013e3182934bb4","article-title":"Is the melatonin receptor type 1 involved in the pathogenesis of glaucoma?","volume":"5","author":"Tosini","year":"2013","journal-title":"J Glaucoma."},{"key":"B69","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0197-0186(94)90100-7","article-title":"Melatonin receptors: localization, molecular pharmacology and physiological significance","volume":"24","author":"Morgan","year":"1994","journal-title":"Neurochem Int."},{"key":"B70","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1006\/exer.2001.1073","article-title":"Melatonin receptor mRNA and protein expression in Xenopus laevis nonpigmented ciliary epithelial cells","volume":"73","author":"Wiechmann","year":"2001","journal-title":"Exp Eye Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1124\/jpet.115.231456","article-title":"Effect of melatonin and 5-methoxycarbonylamino-n-acetyltryptamine on the intraocular pressure of normal and glaucomatous mice","volume":"357","author":"Mart\u00ednez-\u00c1guila","year":"2016","journal-title":"J Pharmacol Exp Ther."},{"key":"B72","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/diagnostics10030138","article-title":"Hypotensive effect of nanomicellar formulation of melatonin and agomelatine in a rat model: significance for glaucoma therapy","volume":"10","author":"Dal Monte","year":"2020","journal-title":"Diagnostics."},{"key":"B73","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1600-079X.2010.00762.x","article-title":"Melatonin: a novel neuroprotectant for the treatment of glaucoma","volume":"48","author":"Belforte","year":"2010","journal-title":"J Pineal Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"e12916","DOI":"10.1111\/jpi.12916","article-title":"Melatonin prevents EAAC1 deletion-induced retinal ganglion cell degeneration by inhibiting apoptosis and senescence","volume":"76","author":"Hu","year":"2024","journal-title":"J Pineal Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-079X.2010.00816.x","article-title":"The role of melatonin in glaucoma: implications concerning pathophysiological relevance and therapeutic potential","volume":"50","author":"Agorastos","year":"2011","journal-title":"J Pineal Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1600-079X.2010.00746.x","article-title":"Molecular and cellular pharmacological properties of 5-methoxycarbonylamino-N-acetyltryptamine (MCA-NAT): a nonspecific MT3 ligand","volume":"48","author":"Vincent","year":"2010","journal-title":"J Pineal Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/ph17040441","article-title":"The therapeutic trip of melatonin eye drops: from the ocular surface to the retina","volume":"17","author":"Rusciano","year":"2024","journal-title":"Pharm Basel Switz."},{"key":"B78","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.3390\/ijms25073999","article-title":"A clinical, pharmacological, and formulation evaluation of melatonin in the treatment of ocular disorders-a systematic review","volume":"25","author":"Romeo","year":"2024","journal-title":"Int J Mol Sci."},{"key":"B79","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1111\/aos.13253","article-title":"Elevated intraocular pressure increases melatonin levels in the aqueous humour","volume":"95","author":"Alkozi","year":"2017","journal-title":"Acta Ophthalmol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1600-079X.2011.00938.x","article-title":"Involvement of carbonic anhydrases in the ocular hypotensive effect of melatonin analogue 5-MCA-NAT","volume":"52","author":"Crooke","year":"2012","journal-title":"J Pineal Res."},{"key":"B81","first-page":"141","article-title":"Natural therapies for ocular disorders, part two: cataracts and glaucoma","volume":"6","author":"Head","year":"2001","journal-title":"Altern Med Rev J Clin Ther."},{"key":"B82","doi-asserted-by":"publisher","first-page":"9084","DOI":"10.3390\/ijms21239084","article-title":"TGF-\u03b2 Induced CTGF expression in human lung epithelial cells through ERK, ADAM17, RSK1, and C\/EBP\u03b2 pathways","volume":"21","author":"Ou","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.3109\/02713683.2016.1143014","article-title":"Immunohistochemical detection of CTGF in the human eye","volume":"41","author":"Van Setten","year":"2016","journal-title":"Curr Eye Res."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1177\/15353702231199466","article-title":"Connective tissue growth factor: Role in trabecular meshwork remodeling and intraocular pressure lowering","volume":"248","author":"Hassan","year":"2023","journal-title":"Exp Biol Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1803239","DOI":"10.1002\/smll.201803239","article-title":"Intracameral delivery of layer-by-layer coated siRNA nanoparticles for glaucoma therapy","volume":"14","author":"Dillinger","year":"2018","journal-title":"Small."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.3390\/genes13081500","article-title":"MiR-18a-5p targets connective tissue growth factor expression and inhibits transforming growth factor \u03b22-induced trabecular meshwork cell contractility","volume":"13","author":"Knox","year":"2022","journal-title":"Genes."},{"key":"B87","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1080\/21691401.2017.1345926","article-title":"A key role of microRNA-26a in the scar formation after glaucoma filtration surgery","volume":"46","author":"Wang","year":"2018","journal-title":"Artif Cells Nanomedicine Biotechnol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"750459","DOI":"10.1155\/2014\/750459","article-title":"The role of epigenetics in the fibrotic processes associated with glaucoma","volume":"2014","author":"McDonnell","year":"2014","journal-title":"J Ophthalmol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41434-020-0166-4","article-title":"Effect of connective tissue growth factor gene editing using adeno-associated virus-mediated CRISPR-Cas9 on rabbit glaucoma filtering surgery outcomes","volume":"28","author":"Lee","year":"2021","journal-title":"Gene Ther."},{"key":"B90","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1016\/j.bbagen.2013.01.005","article-title":"Adenosine, adenosine receptors and glaucoma: an updated overview","volume":"1830","author":"Zhong","year":"2013","journal-title":"Biochim Biophys Acta BBA - Gen Subj."},{"key":"B91","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1006\/exer.1996.0352","article-title":"Localization of adenosine receptor messenger RNAs in the rat eye","volume":"65","author":"Kvanta","year":"1997","journal-title":"Exp Eye Res."},{"key":"B92","first-page":"3016","article-title":"Adenosine A1 receptor modulation of MMP-2 secretion by trabecular meshwork cells","volume":"43","author":"Shearer","year":"2002","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/s00347-005-1216-4","article-title":"Functional significance of adenosine receptors in the eye and their dysregulation in pseudoexfoliation syndrome","volume":"102","author":"Schl\u00f6tzer-Schrehardt","year":"2005","journal-title":"Ophthalmol Z Dtsch Ophthalmol Ges."},{"key":"B94","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1517\/14728222.2014.888416","article-title":"Newer targets for modulation of intraocular pressure: focus on adenosine receptor signaling pathways","volume":"18","author":"Agarwal","year":"2014","journal-title":"Expert Opin Ther Targets."},{"key":"B95","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1021\/acs.jmedchem.5b00828","article-title":"Discovery of molecular therapeutics for glaucoma: challenges, successes, and promising directions","volume":"59","author":"Donegan","year":"2016","journal-title":"J Med Chem."},{"key":"B96","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/13543784.2021.1873276","article-title":"Trabodenoson on trabecular meshwork rejuvenation: a comprehensive review of clinical data","volume":"30","author":"Qiu","year":"2021","journal-title":"Expert Opin Investig Drugs."},{"key":"B97","doi-asserted-by":"publisher","first-page":"9719","DOI":"10.1038\/s41598-020-66350-w","article-title":"A comprehensive map of disease networks and molecular drug discoveries for glaucoma","volume":"10","author":"Wang","year":"2020","journal-title":"Sci Rep."},{"key":"B98","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00441-013-1584-z","article-title":"Challenges in the development of glaucoma neuroprotection therapy","volume":"353","author":"Liu","year":"2013","journal-title":"Cell Tissue Res."},{"key":"B99","doi-asserted-by":"publisher","first-page":"733080","DOI":"10.3389\/fmed.2021.733080","article-title":"Glaucoma clinical research: trends in treatment strategies and drug development","volume":"8","author":"Storgaard","year":"2021","journal-title":"Front Med."},{"key":"B100","doi-asserted-by":"publisher","first-page":"692609","DOI":"10.1155\/2012\/692609","article-title":"Animal models of glaucoma","volume":"2012","author":"Bouhenni","year":"2012","journal-title":"J Biomed Biotechnol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/ceo.13336","article-title":"Neuroprotection in glaucoma: recent advances and clinical translation","volume":"47","author":"Guymer","year":"2019","journal-title":"Clin Experiment Ophthalmol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/ceo.12992","article-title":"DBA\/2J mouse model for experimental glaucoma: pitfalls and problems","volume":"45","author":"Turner","year":"2017","journal-title":"Clin Experiment Ophthalmol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"101193","DOI":"10.1016\/j.mam.2023.101193","article-title":"Neuroprotection in glaucoma: mechanisms beyond intraocular pressure lowering","volume":"92","author":"Tribble","year":"2023","journal-title":"Mol Aspects Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"101160","DOI":"10.1016\/j.preteyeres.2022.101160","article-title":"Endpoints for clinical trials in ophthalmology","volume":"97","author":"Schmetterer","year":"2023","journal-title":"Prog Retin Eye Res."},{"key":"B105","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1167\/iovs.16-19933","article-title":"Clinical utility of optical coherence tomography in glaucoma","volume":"57","author":"Dong","year":"2016","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B106","doi-asserted-by":"publisher","first-page":"9329310","DOI":"10.1155\/2020\/9329310","article-title":"Innovative IOP-independent neuroprotection and neuroregeneration strategies in the pipeline for glaucoma","volume":"2020","author":"Tsai","year":"2020","journal-title":"J Ophthalmol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3389\/fphar.2019.01117","article-title":"Morphological and functional evaluation of oral citicoline therapy in chronic open-angle glaucoma patients: a pilot study with a 2-year follow-up","volume":"10","author":"Lanza","year":"2019","journal-title":"Front Pharmacol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4172\/2155-9570.S3-002","article-title":"Diabetes mellitus and retinal vein occlusion as risk factors for open angle glaucoma and neuroprotective therapies for retinal ganglion cell neuropathy","volume":"3","author":"Bikbova","year":"2011","journal-title":"J Clin Exp Ophthalmol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.2147\/OPTH.S80445","article-title":"Current perspective of neuroprotection and glaucoma","volume":"9","author":"Tian","year":"2015","journal-title":"Clin Ophthalmol Auckl NZ."},{"key":"B110","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1016\/S0039-6257(99)00017-X","article-title":"An experimental basis for implicating excitotoxicity in glaucomatous optic neuropathy","volume":"43","author":"Vorwerk","year":"1999","journal-title":"Surv Ophthalmol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"e70281","DOI":"10.1096\/fj.202400435R","article-title":"FABP5 regulates ROS-NLRP3 inflammasome in glutamate-induced retinal excitotoxic glaucomatous model","volume":"39","author":"Zeng","year":"2025","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1055\/a-2409-2999","article-title":"Erigeron breviscapus: a promising medication for protecting the optic nerve in glaucoma","volume":"90","author":"Cheng","year":"2024","journal-title":"Planta Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12974-022-02626-4","article-title":"GSK872 and necrostatin-1 protect retinal ganglion cells against necroptosis through inhibition of RIP1\/RIP3\/MLKL pathway in glutamate-induced retinal excitotoxic model of glaucoma","volume":"19","author":"Liu","year":"2022","journal-title":"J Neuroinflammation."},{"key":"B114","doi-asserted-by":"publisher","first-page":"e0236450","DOI":"10.1371\/journal.pone.0236450","article-title":"Philanthotoxin-343 attenuates retinal and optic nerve injury, and protects visual function in rats with N-methyl-D-aspartate-induced excitotoxicity","volume":"15","author":"Fazel","year":"2020","journal-title":"PLoS ONE."},{"key":"B115","doi-asserted-by":"publisher","first-page":"e3378","DOI":"10.1002\/jgm.3378","article-title":"MicroRNA-145-5p targeting of TRIM2 mediates the apoptosis of retinal ganglion cells via the PI3K\/AKT signaling pathway in glaucoma","volume":"23","author":"Xu","year":"2021","journal-title":"J Gene Med."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3390\/ijms25021106","article-title":"The role of microRNAs related to apoptosis for n-methyl-d-aspartic acid-induced neuronal cell death in the murine retina","volume":"25","author":"Sone","year":"2024","journal-title":"Int J Mol Sci."},{"key":"B117","first-page":"1618","article-title":"Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine","volume":"37","author":"Vorwerk","year":"1996","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B118","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1442-9071.2006.01146.x","article-title":"Possible role of excitotoxicity in the pathogenesis of glaucoma","volume":"34","author":"Casson","year":"2006","journal-title":"Clin Experiment Ophthalmol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.neuroscience.2017.09.005","article-title":"Permissive role for mGlu1 metabotropic glutamate receptors in excitotoxic retinal degeneration","volume":"363","author":"Liberatore","year":"2017","journal-title":"Neuroscience."},{"key":"B120","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12974-021-02315-8","article-title":"TRPV4-induced M\u00fcller cell gliosis and TNF-\u03b1 elevation-mediated retinal ganglion cell apoptosis in glaucomatous rats via JAK2\/STAT3\/NF-\u03baB pathway","volume":"18","author":"Li","year":"2021","journal-title":"J Neuroinflam."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1002\/cbin.12030","article-title":"Insights into CD154-mediated pathways in ocular hypertensive glaucoma: The role of M\u00fcller cells and P2X7 in retinal neuroprotection and therapeutic potential","volume":"47","author":"Hu","year":"2023","journal-title":"Cell Biol Int."},{"key":"B122","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12974-021-02366-x","article-title":"Interplay between M\u00fcller cells and microglia aggravates retinal inflammatory response in experimental glaucoma","volume":"18","author":"Hu","year":"2021","journal-title":"J Neuroinflam."},{"key":"B123","doi-asserted-by":"publisher","first-page":"101169","DOI":"10.1016\/j.preteyeres.2023.101169","article-title":"Activation of retinal glial cells contributes to the degeneration of ganglion cells in experimental glaucoma","volume":"93","author":"Miao","year":"2023","journal-title":"Prog Retin Eye Res."},{"key":"B124","doi-asserted-by":"publisher","first-page":"811","DOI":"10.18240\/ijo.2023.05.20","article-title":"Mitochondrial dysfunction in glaucomatous degeneration","volume":"16","author":"Zhang","year":"2023","journal-title":"Int J Ophthalmol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.1002\/jcb.29822","article-title":"Retinal proteomics of experimental glaucoma model reveal intraocular pressure-induced mediators of neurodegenerative changes","volume":"121","author":"Mirzaei","year":"2020","journal-title":"J Cell Biochem."},{"key":"B126","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3390\/antiox13060743","article-title":"Administration of bicarbonate protects mitochondria, rescues retinal ganglion cells, and ameliorates visual dysfunction caused by oxidative stress","volume":"13","author":"Bastola","year":"2024","journal-title":"Antioxid Basel Switz."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-020-2456-6","article-title":"Loss of AKAP1 triggers Drp1 dephosphorylation-mediated mitochondrial fission and loss in retinal ganglion cells","volume":"11","author":"Edwards","year":"2020","journal-title":"Cell Death Dis."},{"key":"B128","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.3390\/antiox12112011","article-title":"Targeting mitochondrial dysfunction and oxidative stress to prevent the neurodegeneration of retinal ganglion cells","volume":"12","author":"Catalani","year":"2023","journal-title":"Antioxidants."},{"key":"B129","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3892\/ijmm.2015.2418","article-title":"Crocin protects retinal ganglion cells against H2O2-induced damage through the mitochondrial pathway and activation of NF-\u03baB","volume":"37","author":"Lv","year":"2016","journal-title":"Int J Mol Med."},{"key":"B130","doi-asserted-by":"publisher","first-page":"16253","DOI":"10.3390\/ijms242216253","article-title":"scAAV2-Mediated expression of thioredoxin 2 and C3 transferase prevents retinal ganglion cell death and lowers intraocular pressure in a mouse model of glaucoma","volume":"24","author":"Kim","year":"2023","journal-title":"Int J Mol Sci."},{"key":"B131","doi-asserted-by":"publisher","first-page":"8876","DOI":"10.3390\/ijms25168876","article-title":"AAV-NDI1 therapy provides significant benefit to murine and cellular models of glaucoma","volume":"25","author":"Millington-Ward","year":"2024","journal-title":"Int J Mol Sci."},{"key":"B132","doi-asserted-by":"publisher","first-page":"842","DOI":"10.3109\/02713683.2010.489728","article-title":"Dietary deficiency of vitamin E aggravates retinal ganglion cell death in experimental glaucoma of rats","volume":"35","author":"Ko","year":"2010","journal-title":"Curr Eye Res."},{"key":"B133","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1167\/iovs.18-23806","article-title":"Resveratrol delays retinal ganglion cell loss and attenuates gliosis-related inflammation from ischemia-reperfusion injury","volume":"59","author":"Luo","year":"2018","journal-title":"Investig Opthalmology Vis Sci."},{"key":"B134","doi-asserted-by":"publisher","first-page":"919905","DOI":"10.3389\/fphar.2022.919905","article-title":"Long-term oral administration of naringenin counteracts aging-related retinal degeneration via regulation of mitochondrial dynamics and autophagy","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/APO.0000000000000279","article-title":"Ginkgo biloba extract in ophthalmic and systemic disease, with a focus on normal-tension glaucoma","volume":"9","author":"Labkovich","year":"2020","journal-title":"Asia-Pac J Ophthalmol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1111\/aos.13530","article-title":"The effects of antioxidants on ocular blood flow in patients with glaucoma","volume":"96","author":"Harris","year":"2018","journal-title":"Acta Ophthalmol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3390\/antiox11050886","article-title":"The intertwined roles of oxidative stress and endoplasmic reticulum stress in glaucoma","volume":"11","author":"Hurley","year":"2022","journal-title":"Antioxidants."},{"key":"B138","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1177\/11206721231214297","article-title":"Current trends in targeting the oxidative stress in glaucoma (Review)","volume":"34","author":"Iorga","year":"2024","journal-title":"Eur J Ophthalmol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"30361","DOI":"10.1021\/jacs.4c10457","article-title":"Green-light-triggered and self-calibrated cascade release of nitric oxide and carbon monoxide for synergistic glaucoma therapy","volume":"146","author":"Chen","year":"2024","journal-title":"J Am Chem Soc."},{"key":"B140","doi-asserted-by":"publisher","first-page":"17","DOI":"10.21767\/2171-6625.100017","article-title":"Mitochondrial targeted antioxidant in cerebral ischemia","volume":"6","author":"Ahmed","year":"2015","journal-title":"J Neurol Neurosci"},{"key":"B141","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0079-6123(08)01139-4","article-title":"Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection","volume":"173","author":"Russo","year":"2008","journal-title":"Prog Brain Res."},{"key":"B142","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41514-024-00137-5","article-title":"Author Correction: Reduced glutathione level in the aqueous humor of patients with primary open-angle glaucoma and normal-tension glaucoma","volume":"10","author":"Sato","year":"2024","journal-title":"NPJ Aging."},{"key":"B143","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s40135-019-00212-1","article-title":"Immunomodulation as a neuroprotective strategy for glaucoma treatment","volume":"7","author":"Bari\u015f","year":"2019","journal-title":"Curr Ophthalmol Rep."},{"key":"B144","doi-asserted-by":"publisher","first-page":"e99719","DOI":"10.1371\/journal.pone.0099719","article-title":"Rapamycin is neuroprotective in a rat chronic hypertensive glaucoma model","volume":"9","author":"Su","year":"2014","journal-title":"PLoS ONE."},{"key":"B145","doi-asserted-by":"publisher","first-page":"e43602","DOI":"10.1371\/journal.pone.0043602","article-title":"Early reduction of microglia activation by irradiation in a model of chronic glaucoma","volume":"7","author":"Bosco","year":"2012","journal-title":"PLoS ONE."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1167\/iovs.07-1337","article-title":"Reduced retina microglial activation and improved optic nerve integrity with minocycline treatment in the DBA\/2J mouse model of glaucoma","volume":"49","author":"Bosco","year":"2008","journal-title":"Investig Opthalmology Vis Sci."},{"key":"B147","doi-asserted-by":"publisher","first-page":"e40065","DOI":"10.1371\/journal.pone.0040065","article-title":"Etanercept, a widely used inhibitor of tumor necrosis factor-\u03b1 (TNF- \u03b1), prevents retinal ganglion cell loss in a rat model of glaucoma","volume":"7","author":"Roh","year":"2012","journal-title":"PLoS ONE."},{"key":"B148","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12974-015-0333-5","article-title":"Adenosine A2AR blockade prevents neuroinflammation-induced death of retinal ganglion cells caused by elevated pressure","volume":"12","author":"Madeira","year":"2015","journal-title":"J Neuroinflammation."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1354569","DOI":"10.3389\/fncel.2024.1354569","article-title":"Glaucoma: from pathogenic mechanisms to retinal glial cell response to damage","volume":"18","author":"Fern\u00e1ndez-Albarral","year":"2024","journal-title":"Front Cell Neurosci."},{"key":"B150","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1167\/iovs.18-25700","article-title":"Early optic nerve head glial proliferation and jak-stat pathway activation in chronic experimental glaucoma","volume":"60","author":"Lozano","year":"2019","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B151","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/ICU.0000000000000125","article-title":"Glial cell interactions and glaucoma","volume":"26","author":"Chong","year":"2015","journal-title":"Curr Opin Ophthalmol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1021\/acs.biomac.2c01381","article-title":"Targeted microglial attenuation through dendrimer-drug conjugates improves glaucoma neuroprotection","volume":"24","author":"Pitha","year":"2023","journal-title":"Biomacromolecules."},{"key":"B153","doi-asserted-by":"publisher","first-page":"9821","DOI":"10.1038\/s41598-018-28183-6","article-title":"S100B immunization triggers NF\u03baB and complement activation in an autoimmune glaucoma model","volume":"8","author":"Reinehr","year":"2018","journal-title":"Sci Rep."},{"key":"B154","doi-asserted-by":"publisher","first-page":"e104416","DOI":"10.1371\/journal.pone.0104416","article-title":"Oral microbiome link to neurodegeneration in glaucoma","volume":"9","author":"Astafurov","year":"2014","journal-title":"PLoS ONE."},{"key":"B155","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.3892\/mmr.2017.8137","article-title":"P2X7 receptor antagonist protects retinal ganglion cells by inhibiting microglial activation in a rat chronic ocular hypertension model","volume":"17","author":"Dong","year":"2018","journal-title":"Mol Med Rep."},{"key":"B156","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/ceo.12289","article-title":"Immune priming and experimental glaucoma: the effect of prior systemic lipopolysaccharide challenge on tissue outcomes after optic nerve injury","volume":"42","author":"Narayan","year":"2014","journal-title":"Clin Experiment Ophthalmol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1002\/glia.24600","article-title":"MicroRNA-146a-5p protects retinal ganglion cells through reducing neuroinflammation in experimental glaucoma","volume":"72","author":"Zhou","year":"2024","journal-title":"Glia."},{"key":"B158","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s13167-023-00336-2","article-title":"The correlation between primary open-angle glaucoma (POAG) and gut microbiota: a pilot study towards predictive, preventive, and personalized medicine","volume":"14","author":"Chen","year":"2023","journal-title":"EPMA J."},{"key":"B159","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.nbd.2016.05.002","article-title":"The glial cell modulator ibudilast attenuates neuroinflammation and enhances retinal ganglion cell viability in glaucoma through protein kinase A signaling","volume":"93","author":"Cueva Vargas","year":"2016","journal-title":"Neurobiol Dis."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1172\/JCI61135","article-title":"Radiation treatment inhibits monocyte entry into the optic nerve head and prevents neuronal damage in a mouse model of glaucoma","volume":"122","author":"Howell","year":"2012","journal-title":"J Clin Invest."},{"key":"B161","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.neuroscience.2018.08.016","article-title":"Nodes of ranvier in glaucoma","volume":"390","author":"Smith","year":"2018","journal-title":"Neuroscience."},{"key":"B162","first-page":"942","article-title":"T-cell profiling of glaucoma patients","volume":"63","author":"Kuehn","year":"2022","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B163","first-page":"3922","article-title":"Increased T-regulatory cell activity protects retinal ganglion cells in glaucoma","volume":"64","author":"Zeng","year":"2023","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B164","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0079-6123(08)01128-X","article-title":"TNF-\u03b1 signaling in glaucomatous neurodegeneration","volume":"173","author":"Tezel","year":"2008","journal-title":"Prog Brain Res."},{"key":"B165","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1167\/iovs.05-0299","article-title":"TNF-\u03b1-induced optic nerve degeneration and nuclear factor-\u03baB p65","volume":"47","author":"Kitaoka","year":"2006","journal-title":"Investig Opthalmology Vis Sci."},{"key":"B166","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1167\/iovs.16-19153","article-title":"Antioxidant treatment limits neuroinflammation in experimental glaucoma","volume":"57","author":"Yang","year":"2016","journal-title":"Investig Opthalmology Vis Sci."},{"key":"B167","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00347-018-0658-4","article-title":"Autoimmunit\u00e4t und glaukom","volume":"116","author":"Bell","year":"2019","journal-title":"Ophthalmol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/glia.20537","article-title":"Transcriptional regulation of scar gene expression in primary astrocytes","volume":"55","author":"Gris","year":"2007","journal-title":"Glia."},{"key":"B169","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S0301-0082(00)00017-4","article-title":"What role(s) for TGF\u03b1 in the central nervous system?","volume":"62","author":"Junier","year":"2000","journal-title":"Prog Neurobiol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.cytogfr.2015.07.007","article-title":"Ciliary neurotrophic factor (CNTF): new facets of an old molecule for treating neurodegenerative and metabolic syndrome pathologies","volume":"26","author":"Pasquin","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1310226","DOI":"10.3389\/fopht.2023.1310226","article-title":"Glial cells as a promising therapeutic target of glaucoma: beyond the IOP","volume":"3","author":"Shinozaki","year":"2024","journal-title":"Front Ophthalmol."},{"key":"B172","first-page":"799","article-title":"Ciliary neurotrophic factor in patients with primary open-angle glaucoma and age-related cataract","volume":"23","author":"Shpak","year":"2017","journal-title":"Mol Vis."},{"key":"B173","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s12017-015-8360-z","article-title":"NGF expression in reelin-deprived retinal cells: a potential neuroprotective","volume":"17","author":"Balzamino","year":"2015","journal-title":"Effect Neuromolecular Med."},{"key":"B174","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-022-05407-2","article-title":"Peptains block retinal ganglion cell death in animal models of ocular hypertension: implications for neuroprotection in glaucoma","volume":"13","author":"Nam","year":"2022","journal-title":"Cell Death Dis."},{"key":"B175","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1167\/iovs.19-27389","article-title":"Increased optic nerve head capillary blood flow in early primary open-angle glaucoma","volume":"60","author":"Gardiner","year":"2019","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B176","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1167\/iovs.11-8552","article-title":"Relationship among visual field, blood flow, and neural structure measurements in glaucoma","volume":"53","author":"Hwang","year":"2012","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B177","first-page":"568","article-title":"Vascular reactivity of optic nerve head and retinal blood vessels in glaucoma\u2013a review","volume":"17","author":"Venkataraman","year":"1994","journal-title":"Microcirc N Y N."},{"key":"B178","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1167\/iovs.15-17864","article-title":"Platelet-derived growth factor preserves retinal synapses in a rat model of ocular hypertension","volume":"57","author":"Chong","year":"2016","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B179","doi-asserted-by":"publisher","first-page":"4703","DOI":"10.1167\/iovs.21783","article-title":"Retinal astrocytes and GABAergic wide-field amacrine cells express PDGFR\u03b1: connection to retinal ganglion cell neuroprotection by PDGF-AA","volume":"58","author":"Takahama","year":"2017","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B180","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1089\/ten.2004.10.1617","article-title":"Sustained secretion of ciliary neurotrophic factor to the vitreous, using the encapsulated cell therapy-based NT-501 intraocular device","volume":"10","author":"Thanos","year":"2004","journal-title":"Tissue Eng."},{"key":"B181","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1073\/pnas.0600236103","article-title":"Ciliary neurotrophic factor (CNTF) for human retinal degeneration: Phase I trial of CNTF delivered by encapsulated cell intraocular implants","volume":"103","author":"Sieving","year":"2006","journal-title":"Proc Natl Acad Sci."},{"key":"B182","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1517\/14712598.6.7.717","article-title":"Application of encapsulated cell technology for retinal degenerative diseases","volume":"6","author":"Tao","year":"2006","journal-title":"Expert Opin Biol Ther."},{"key":"B183","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ajo.2013.03.021","article-title":"Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa","volume":"156","author":"Birch","year":"2013","journal-title":"Am J Ophthalmol."},{"key":"B184","doi-asserted-by":"publisher","first-page":"6241","DOI":"10.1073\/pnas.1018987108","article-title":"Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration","volume":"108","author":"Zhang","year":"2011","journal-title":"Proc Natl Acad Sci."},{"key":"B185","unstructured":"Goldberg\n              JL\n            \n          \n          CNTF Cell implants for glaucoma: a phase I study\n          \n          2016"},{"key":"B186","doi-asserted-by":"publisher","first-page":"e1356956","DOI":"10.1080\/19420889.2017.1356956","article-title":"Nicotinamide treatment robustly protects from inherited mouse glaucoma","volume":"11","author":"Williams","year":"2018","journal-title":"Commun Integr Biol."},{"key":"B187","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3390\/pharmaceutics13060893","article-title":"Systemic treatment with nicotinamide riboside is protective in two mouse models of retinal ganglion cell damage","volume":"13","author":"Zhang","year":"2021","journal-title":"Pharmaceutics."},{"key":"B188","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.3390\/nu14061162","article-title":"Neuroprotective effects of nicotinamide (Vitamin B3) on neurodegeneration in diabetic rat retinas","volume":"14","author":"Jung","year":"2022","journal-title":"Nutrients."},{"key":"B189","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.3390\/jpm12111884","article-title":"Neuroprotection in glaucoma: basic aspects and clinical relevance","volume":"12","author":"Kuo","year":"2022","journal-title":"J Pers Med."},{"key":"B190","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.3390\/cells10061402","article-title":"Neuroprotection in glaucoma: NAD+\/NADH redox state as a potential biomarker and therapeutic target","volume":"10","author":"Petriti","year":"2021","journal-title":"Cells."},{"key":"B191","doi-asserted-by":"publisher","first-page":"101988","DOI":"10.1016\/j.redox.2021.101988","article-title":"Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction","volume":"43","author":"Tribble","year":"2021","journal-title":"Redox Biol"},{"key":"B192","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3389\/fnins.2017.00232","article-title":"Nicotinamide and WLDS act together to prevent neurodegeneration in glaucoma","volume":"11","author":"Williams","year":"2017","journal-title":"Front Neurosci."},{"key":"B193","doi-asserted-by":"publisher","first-page":"957034","DOI":"10.3389\/fnins.2022.957034","article-title":"Stretch stress propels glutamine dependency and glycolysis in optic nerve head astrocytes","volume":"16","author":"Pappenhagen","year":"2022","journal-title":"Front Neurosci."},{"key":"B194","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.3390\/biomedicines12081655","article-title":"Nicotinamide: bright potential in glaucoma management","volume":"12","author":"Babighian","year":"2024","journal-title":"Biomedicines."},{"key":"B195","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.3390\/nu12071910","article-title":"Nicotinamide-rich diet in DBA\/2J mice preserves retinal ganglion cell metabolic function as assessed by PERG adaptation to flicker","volume":"12","author":"Chou","year":"2020","journal-title":"Nutrients."},{"key":"B196","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/ceo.13818","article-title":"Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: a crossover randomised clinical trial","volume":"48","author":"Hui","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"key":"B197","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s40478-024-01850-8","article-title":"Oral nicotinamide provides robust, dose-dependent structural and metabolic neuroprotection of retinal ganglion cells in experimental glaucoma","volume":"12","author":"Cimaglia","year":"2024","journal-title":"Acta Neuropathol Commun."},{"key":"B198","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/archopht.124.5.665","article-title":"Effect of systemic administration of simvastatin on retinal circulation","volume":"124","author":"Nagaoka","year":"2006","journal-title":"Arch Ophthalmol."},{"key":"B199","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/82219","article-title":"Statins as a newly recognized type of immunomodulator","volume":"6","author":"Kwak","year":"2000","journal-title":"Nat Med."},{"key":"B200","doi-asserted-by":"publisher","first-page":"12500","DOI":"10.3390\/ijms222212500","article-title":"Neuroprotective effect of statins in a rat model of chronic ocular hypertension","volume":"22","author":"Kim","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B201","doi-asserted-by":"publisher","first-page":"e0154800","DOI":"10.1371\/journal.pone.0154800","article-title":"Neuroprotective effects of low-dose statins in the retinal ultrastructure of hypercholesterolemic rabbits","volume":"11","author":"Fern\u00e1ndez-Navarro","year":"2016","journal-title":"PLoS ONE."},{"key":"B202","doi-asserted-by":"publisher","first-page":"124","DOI":"10.4236\/ojoph.2014.44021","article-title":"The emerging role of statins in glaucoma pathological mechanisms and therapeutics","volume":"4","author":"Pokrovskaya","year":"2014","journal-title":"Open J Ophthalmol."},{"key":"B203","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3892\/etm.2017.5353","article-title":"Effects of atorvastatin on porcine aqueous humour outflow and trabecular meshwork cells","volume":"15","author":"Cong","year":"2018","journal-title":"Exp Ther Med."},{"key":"B204","doi-asserted-by":"publisher","first-page":"109781","DOI":"10.1016\/j.exer.2024.109781","article-title":"Modulation of TRPV4-mediated TNF-\u03b1 expression in M\u00fcller glia and subsequent RGC apoptosis by statins","volume":"239","author":"Choi","year":"2024","journal-title":"Exp Eye Res."},{"key":"B205","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijmm.2022.5132","article-title":"Atorvastatin reduces IOP in ocular hypertension in vivo and suppresses ECM in trabecular meshwork perhaps via FGD4","volume":"49","author":"Song","year":"2022","journal-title":"Int J Mol Med."},{"key":"B206","doi-asserted-by":"publisher","first-page":"21","DOI":"10.17305\/bjbms.2016.830","article-title":"Higher serum lipids and oxidative stress in patients with normal tension glaucoma, but not pseudoexfoliative glaucoma","volume":"16","author":"Yilmaz","year":"2016","journal-title":"Bosn J Basic Med Sci."},{"key":"B207","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ogla.2024.07.008","article-title":"Associations between statin use and glaucoma in the all of us research program","volume":"7","author":"Lee","year":"2024","journal-title":"Ophthalmol Glaucoma."},{"key":"B208","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1001\/jamaophthalmol.2016.5406","article-title":"Association of daily dosage and type of statin agent with risk of open-angle glaucoma","volume":"135","author":"Talwar","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"B209","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.neulet.2015.06.002","article-title":"Neuroprotective effect of epigallocatechin-3-gallate in a mouse model of chronic glaucoma","volume":"600","author":"Shen","year":"2015","journal-title":"Neurosci Lett."},{"key":"B210","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.3892\/etm.2021.10669","article-title":"Neuroprotective role of epigallocatechin-3-gallate in acute glaucoma via the nuclear factor-\u03baB signalling pathway","volume":"22","author":"Zhang","year":"2021","journal-title":"Exp Ther Med."},{"key":"B211","doi-asserted-by":"publisher","first-page":"e25456","DOI":"10.1371\/journal.pone.0025456","article-title":"Neuroprotective effect of combination therapy of glatiramer acetate and epigallocatechin-3-gallate in neuroinflammation","volume":"6","author":"Herges","year":"2011","journal-title":"PLoS ONE."},{"key":"B212","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4196\/kjpp.2016.20.1.41","article-title":"Epigallocatechin-3-gallate rescues LPS-impaired adult hippocampal neurogenesis through suppressing the TLR4-NF-\u03baB signaling pathway in mice","volume":"20","author":"Seong","year":"2016","journal-title":"Korean J Physiol Pharmacol."},{"key":"B213","doi-asserted-by":"publisher","first-page":"340","DOI":"10.5114\/fn.2019.90819","article-title":"Epigallocatechin gallate enhances the motor neuron survival and functional recovery after brachial plexus root avulsion by regulating FIG4","volume":"57","author":"Tang","year":"2019","journal-title":"Folia Neuropathol."},{"key":"B214","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/1028415X.2018.1500124","article-title":"The green tea polyphenolic catechin epigallocatechin gallate and neuroprotection","volume":"23","author":"Khalatbary","year":"2020","journal-title":"Nutr Neurosci."},{"key":"B215","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.neuroscience.2017.01.025","article-title":"Involvement of PKC\u03b1 and ERK1\/2 signaling pathways in EGCG's protection against stress-induced neural injuries in Wistar rats","volume":"346","author":"Zhao","year":"2017","journal-title":"Neuroscience."},{"key":"B216","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.3892\/etm.2018.5936","volume":"15","author":"Feng","year":"2018","journal-title":"Exp Ther Med."},{"key":"B217","doi-asserted-by":"publisher","first-page":"e0192083","DOI":"10.1371\/journal.pone.0192083","article-title":"Epigallocatechin-3-gallate confers protection against corticosterone-induced neuron injuries via restoring extracellular signal-regulated kinase 1\/2 and phosphatidylinositol-3 kinase\/protein kinase B signaling pathways","volume":"13","author":"Zhao","year":"2018","journal-title":"PLoS ONE."},{"key":"B218","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.neulet.2010.05.020","article-title":"Neuroprotective effects of Epigallocatechin-3-gallate (EGCG) in optic nerve crush model in rats","volume":"479","author":"Xie","year":"2010","journal-title":"Neurosci Lett."},{"key":"B219","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1691\/ph.2012.1642","article-title":"Forskolin and derivatives as tools for studying the role of cAMP","volume":"67","author":"Alasbahi","year":"2012","journal-title":"Pharm."},{"key":"B220","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.3390\/nu11122931","article-title":"Protective efficacy of a dietary supplement based on forskolin, homotaurine, spearmint extract, and group B vitamins in a mouse model of optic nerve injury","volume":"11","author":"Locri","year":"2019","journal-title":"Nutrients."},{"key":"B221","doi-asserted-by":"publisher","first-page":"e23001","DOI":"10.7554\/eLife.23001","article-title":"Total biosynthesis of the cyclic AMP booster forskolin from Coleus forskohlii","volume":"6","author":"Pateraki","year":"2017","journal-title":"Elife"},{"key":"B222","doi-asserted-by":"publisher","first-page":"199","DOI":"10.4103\/0022-3859.101396","article-title":"Forskolin: upcoming antiglaucoma molecule","volume":"58","author":"Wagh","year":"2012","journal-title":"J Postgrad Med."},{"key":"B223","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.sjopt.2015.02.003","article-title":"Efficacy and safety of 1% forskolin eye drops in open angle glaucoma - An open label study","volume":"29","author":"Majeed","year":"2015","journal-title":"Saudi J Ophthalmol."},{"key":"B224","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1089\/jop.2012.0021","article-title":"Oral administration of forskolin and rutin contributes to intraocular pressure control in primary open angle glaucoma patients under maximum tolerated medical therapy","volume":"28","author":"Vetrugno","year":"2012","journal-title":"J Ocul Pharmacol Ther."},{"key":"B225","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.3390\/biomedicines11051478","article-title":"Neuroprotective effect of a nutritional supplement containing spearmint extract, forskolin, homotaurine and group B vitamins in a mouse model of transient ocular hypertension","volume":"11","author":"Satriano","year":"2023","journal-title":"Biomedicines."},{"key":"B226","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.3390\/nu12103158","article-title":"Natural products: evidence for neuroprotection to be exploited in glaucoma","volume":"12","author":"Adornetto","year":"2020","journal-title":"Nutrients."},{"key":"B227","first-page":"718","article-title":"Intravitreal injection of forskolin, homotaurine, and L-carnosine affords neuroprotection to retinal ganglion cells following retinal ischemic injury","volume":"21","author":"Russo","year":"2015","journal-title":"Mol Vis."},{"key":"B228","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.3390\/nu12041189","article-title":"A dietary combination of forskolin with homotaurine, spearmint and b vitamins protects injured retinal ganglion cells in a rodent model of hypertensive glaucoma","volume":"12","author":"Cammalleri","year":"2020","journal-title":"Nutrients."},{"key":"B229","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/eye.2011.82","article-title":"Novel drug delivery systems for glaucoma","volume":"25","author":"Lavik","year":"2011","journal-title":"Eye Lond Engl."},{"key":"B230","doi-asserted-by":"publisher","first-page":"4","DOI":"10.17925\/USOR.2023.17.1.4","article-title":"iDose TR Sustained-release travoprost implant for the treatment of glaucoma","volume":"17","author":"Ichhpujani","year":"2023","journal-title":"Ophthalmology"},{"key":"B231","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2020.01.057","article-title":"Advances and limitations of drug delivery systems formulated as eye drops","volume":"321","author":"Jumelle","year":"2020","journal-title":"J Control Release."},{"key":"B232","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3390\/gels7030130","article-title":"Gel-based materials for ophthalmic drug delivery","volume":"7","author":"Cassano","year":"2021","journal-title":"Gels."},{"key":"B233","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40123-020-00257-7","article-title":"Therapies based on nanoparticles for eye drug delivery","volume":"9","author":"Meza-Rios","year":"2020","journal-title":"Ophthalmol Ther."},{"key":"B234","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40265-019-01248-0","article-title":"24-Month Phase I\/II clinical trial of bimatoprost sustained-release implant (bimatoprost SR) in glaucoma patients","volume":"80","author":"Craven","year":"2020","journal-title":"Drugs."},{"key":"B235","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40265-023-01973-7","article-title":"Efficacy and safety of the travoprost intraocular implant in reducing topical IOP-lowering medication burden in patients with open-angle glaucoma or ocular hypertension","volume":"84","author":"Berdahl","year":"2024","journal-title":"Drugs."},{"key":"B236","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40123-024-00898-y","article-title":"Travoprost intracameral implant for open-angle glaucoma or ocular hypertension: 12-month results of a randomized, double-masked trial","volume":"13","author":"Sarkisian","year":"2024","journal-title":"Ophthalmol Ther."},{"key":"B237","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.3390\/app10155151","article-title":"Contact lenses as drug delivery system for glaucoma: a review","volume":"10","author":"Peral","year":"2020","journal-title":"Appl Sci."},{"key":"B238","doi-asserted-by":"publisher","first-page":"2219419","DOI":"10.1080\/10717544.2023.2219419","article-title":"Therapeutic applications of contact lens-based drug delivery systems in ophthalmic diseases","volume":"30","author":"Zhao","year":"2023","journal-title":"Drug Deliv."},{"key":"B239","doi-asserted-by":"publisher","first-page":"16578","DOI":"10.1039\/C9RA02858G","article-title":"Drug-eluting contact lens containing cyclosporine-loaded cholesterol-hyaluronate micelles for dry eye syndrome","volume":"9","author":"Mun","year":"2019","journal-title":"RSC Adv."},{"key":"B240","doi-asserted-by":"publisher","first-page":"34194","DOI":"10.1038\/srep34194","article-title":"Ocular drug delivery through pHEMA-hydrogel contact lenses co-loaded with lipophilic vitamins","volume":"6","author":"Lee","year":"2016","journal-title":"Sci Rep."},{"key":"B241","doi-asserted-by":"publisher","first-page":"1246974","DOI":"10.3389\/fbioe.2023.1246974","article-title":"Recent development of polymer nanomicelles in the treatment of eye diseases","volume":"11","author":"Cai","year":"2023","journal-title":"Front Bioeng Biotechnol."},{"key":"B242","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3390\/pharmaceutics15020625","article-title":"Innovation in the development of synthetic and natural ocular drug delivery systems for eye diseases treatment: focusing on drug-loaded ocular inserts, contacts, and intraocular lenses","volume":"15","author":"Pelusi","year":"2023","journal-title":"Pharmaceutics."},{"key":"B243","doi-asserted-by":"publisher","first-page":"215","DOI":"10.4314\/tjpr.v23i1.27","article-title":"Glaucoma: a review of current management, patients' adherence, direct and indirect cost, and barriers to drug delivery","volume":"23","author":"Alshammari","year":"2024","journal-title":"Trop J Pharm Res."},{"key":"B244","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/vop.12843","article-title":"Medical anti-glaucoma therapy: beyond the drop","volume":"1","author":"Miller","year":"2021","journal-title":"Vet Ophthalmol."},{"key":"B245","doi-asserted-by":"publisher","first-page":"8639","DOI":"10.1038\/s41598-017-09379-8","article-title":"Long term glaucoma drug delivery using a topically retained gel\/microsphere eye drop","volume":"7","author":"Fedorchak","year":"2017","journal-title":"Sci Rep."},{"key":"B246","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.2147\/OPTH.S48766","article-title":"Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes","volume":"7","author":"Shafiee","year":"2013","journal-title":"Clin Ophthalmol."},{"key":"B247","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.ophtha.2017.04.022","article-title":"Long-term safety and efficacy of a sustained-release bimatoprost ocular ring","volume":"124","author":"Brandt","year":"2017","journal-title":"Ophthalmology."},{"key":"B248","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ajo.2016.11.020","article-title":"Bimatoprost sustained-release implants for glaucoma therapy: 6-month results from a phase I\/II clinical trial","volume":"175","author":"Lewis","year":"2017","journal-title":"Am J Ophthalmol."},{"key":"B249","first-page":"3548","article-title":"Preclinical evaluation of ENV515 (travoprost) intracameral implant - clinical candidate for treatment of glaucoma targeting six-month duration of action","volume":"55","author":"Navratil","year":"2014","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B250","unstructured":"Therapeutics E. Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase 2 Data Demonstrating 11-Month Duration-of-Action After a Single Dose in Patients With Glaucoma."},{"key":"B251","first-page":"5270","article-title":"Intracameral conversion of travoprost to travoprost acid in the normotensive beagle dog model","volume":"55","author":"Trevino","year":"2014","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B252","first-page":"4591","article-title":"Long-term intraocular pressure (IOP) control by means of a novel biodegradable intracameral (IC) latanoprost free acid (LFA) implant","volume":"58","author":"Komaromy","year":"2017","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B253","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jconrel.2017.11.008","article-title":"Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent","volume":"269","author":"Kim","year":"2018","journal-title":"J Control Release."},{"key":"B254","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1167\/iovs.16-19585","article-title":"Biocompatibility and pharmacokinetic analysis of an intracameral polycaprolactone drug delivery implant for glaucoma","volume":"57","author":"Kim","year":"2016","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B255","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.1111\/bph.14024","article-title":"Principles of pharmacology in the eye","volume":"174","author":"Awwad","year":"2017","journal-title":"Br J Pharmacol."},{"key":"B256","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ijpharm.2018.07.012","article-title":"Treatment merits of Latanoprost\/Thymoquinone - Encapsulated liposome for glaucomatus rabbits","volume":"548","author":"Fahmy","year":"2018","journal-title":"Int J Pharm."},{"key":"B257","unstructured":""},{"key":"B258","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41392-022-01134-4","article-title":"Stem cell-based therapy for human diseases","volume":"7","author":"Hoang","year":"2022","journal-title":"Signal Transduct Target Ther."},{"key":"B259","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.18240\/ijo.2022.09.17","article-title":"Ocular stem cells: a narrative review of current clinical trials","volume":"15","author":"Sotiropulos","year":"2022","journal-title":"Int J Ophthalmol."},{"key":"B260","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.2147\/OPTH.S372114","article-title":"Utilization of modified induced pluripotent stem cells as the advance therapy of glaucoma: a systematic review","volume":"16","author":"Rizkiawan","year":"2022","journal-title":"Clin Ophthalmol Auckl NZ."},{"key":"B261","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1167\/iovs.12-11056","article-title":"Stem cells from trabecular meshwork home to TM tissue in vivo","volume":"54","author":"Du","year":"2013","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B262","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/stem.1364","article-title":"Transplantation of mesenchymal stem cells promotes tissue regeneration in a glaucoma model through laser-induced paracrine factor secretion and progenitor cell recruitment","volume":"31","author":"Manuguerra-Gagn\u00c9","year":"2013","journal-title":"Stem Cells."},{"key":"B263","doi-asserted-by":"publisher","first-page":"7499","DOI":"10.1167\/iovs.14-14872","article-title":"Identification of adult stem cells in schwalbe's line region of the primate eye","volume":"55","author":"Braunger","year":"2014","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B264","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s13287-015-0168-0","article-title":"Intraocular pressure reduction and neuroprotection conferred by bone marrow-derived mesenchymal stem cells in an animal model of glaucoma","volume":"6","author":"Roubeix","year":"2015","journal-title":"Stem Cell Res Ther."},{"key":"B265","doi-asserted-by":"publisher","first-page":"7160","DOI":"10.1096\/fj.201902326R","article-title":"Adipose-derived stem cells integrate into trabecular meshwork with glaucoma treatment potential","volume":"34","author":"Zhou","year":"2020","journal-title":"FASEB J."},{"key":"B266","doi-asserted-by":"publisher","first-page":"12251","DOI":"10.1038\/s41598-018-30834-7","article-title":"Improving stem cell delivery to the trabecular meshwork using magnetic nanoparticles","volume":"8","author":"Snider","year":"2018","journal-title":"Sci Rep."},{"key":"B267","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/term.2488","article-title":"Characterizing differences between MSCs and TM cells: Toward autologous stem cell therapies for the glaucomatous trabecular meshwork","volume":"12","author":"Snider","year":"2018","journal-title":"J Tissue Eng Regen Med."},{"key":"B268","doi-asserted-by":"publisher","first-page":"101063","DOI":"10.1016\/j.preteyeres.2022.101063","article-title":"A novel glaucoma approach: stem cell regeneration of the trabecular meshwork","volume":"90","author":"Coulon","year":"2022","journal-title":"Prog Retin Eye Res."},{"key":"B269","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/stem.1885","article-title":"Induced pluripotent stem cells restore function in a human cell loss model of open-angle glaucoma","volume":"33","author":"Abu-Hassan DW Li","year":"2015","journal-title":"Stem Cells."},{"key":"B270","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/sctm.16-0428","article-title":"Bone marrow-derived mesenchymal stem cells-derived exosomes promote survival of retinal ganglion cells through miRNA-dependent mechanisms","volume":"6","author":"Mead","year":"2017","journal-title":"Stem Cells Transl Med."},{"key":"B271","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/5584_2018_219","article-title":"Therapeutic potential of mesenchymal stem cell-derived exosomes in the treatment of eye diseases","volume":"1089","author":"Harrell","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"B272","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10633-021-09817-z","article-title":"Retinal function after intravitreal injection of autologous bone marrow-derived mesenchymal stromal cells in advanced glaucoma","volume":"143","author":"Vilela","year":"2021","journal-title":"Doc Ophthalmol Adv Ophthalmol."},{"key":"B273","doi-asserted-by":"publisher","first-page":"80","DOI":"10.22608\/APO.2016126","article-title":"The pathway from genes to gene therapy in glaucoma: a review of possibilities for using genes as glaucoma drugs","volume":"6","author":"Borr\u00e1s","year":"2017","journal-title":"Asia-Pac J Ophthalmol Phila Pa."},{"key":"B274","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3390\/biom11040581","article-title":"Use of gene therapy in retinal ganglion cell neuroprotection: current concepts and future directions","volume":"11","author":"Rhee","year":"2021","journal-title":"Biomolecules."},{"key":"B275","doi-asserted-by":"publisher","first-page":"119","DOI":"10.15283\/ijsc17029","article-title":"Glaucoma, stem cells, and gene therapy: where are we now?","volume":"10","author":"Daliri","year":"2017","journal-title":"Int J Stem Cells."},{"key":"B276","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/gt.2008.178","article-title":"Cellular tropism and transduction properties of seven adeno-associated viral vector serotypes in adult retina after intravitreal injection","volume":"16","author":"Hellstr\u00f6m","year":"2009","journal-title":"Gene Ther."},{"key":"B277","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/gt.2013.64","article-title":"Tyrosine capsid-mutant AAV vectors for gene delivery to the canine retina from a subretinal or intravitreal approach","volume":"21","author":"Mowat","year":"2014","journal-title":"Gene Ther."},{"key":"B278","doi-asserted-by":"publisher","first-page":"e7108948","DOI":"10.1155\/2018\/7108948","article-title":"Progress in gene therapy to prevent retinal ganglion cell loss in glaucoma and leber's hereditary optic neuropathy","volume":"2018","author":"Ratican","year":"2018","journal-title":"Neural Plast."},{"key":"B279","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/01926230701197107","article-title":"Review of the application of RNA interference technology in the pharmaceutical industry","volume":"35","author":"Martineau","year":"2007","journal-title":"Toxicol Pathol."},{"key":"B280","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1186\/s12967-022-03747-3","article-title":"Current strategies employed in the manipulation of gene expression for clinical purposes","volume":"20","author":"Tsai","year":"2022","journal-title":"J Transl Med."},{"key":"B281","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.ymthe.2019.12.012","article-title":"Gene therapy for glaucoma by ciliary body aquaporin 1 disruption using CRISPR-Cas9","volume":"28","author":"Wu","year":"2020","journal-title":"Mol Ther."},{"key":"B282","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-022-04134-w","article-title":"Prostaglandin-based rAAV-mediated glaucoma gene therapy in Brown Norway rats","volume":"5","author":"Chern","year":"2022","journal-title":"Commun Biol."},{"key":"B283","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/jamaophthalmol.2014.4747","article-title":"Prevention of nocturnal elevation of intraocular pressure by gene transfer of dominant-negative RhoA in rats","volume":"133","author":"Borr\u00e1s","year":"2015","journal-title":"JAMA Ophthalmol."},{"key":"B284","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.ymthe.2019.04.021","article-title":"Lentiviral vector-mediated expression of Exoenzyme C3 transferase lowers intraocular pressure in monkeys","volume":"27","author":"Tan","year":"2019","journal-title":"Mol Ther."},{"key":"B285","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.omtm.2019.11.017","article-title":"C3 transferase-expressing scAAV2 transduces ocular anterior segment tissues and lowers intraocular pressure in mouse and monkey","volume":"17","author":"Tan","year":"2020","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B286","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/gt.2016.14","article-title":"Inducible scAAV2 GREMMP1 lowers IOP long-term in a large animal model for steroid-induced glaucoma gene therapy","volume":"23","author":"Borr\u00e1s","year":"2016","journal-title":"Gene Ther."},{"key":"B287","doi-asserted-by":"publisher","first-page":"11199","DOI":"10.1073\/pnas.1706193114","article-title":"CRISPR-Cas9\u2013based treatment of myocilin-associated glaucoma","volume":"114","author":"Jain","year":"2017","journal-title":"Proc Natl Acad Sci."},{"key":"B288","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/ICU.0000000000001016","article-title":"Future directions of glaucoma treatment: emerging gene, neuroprotection, nanomedicine, stem cell, and vascular therapies","volume":"35","author":"Ciociola","year":"2024","journal-title":"Curr Opin Ophthalmol."},{"key":"B289","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.3892\/mmr.2020.10955","article-title":"Integrative analysis of an lncRNA-associated competing endogenous RNA network in human trabecular meshwork cells under oxidative stress","volume":"21","author":"Yao","year":"2020","journal-title":"Mol Med Rep."},{"key":"B290","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.3390\/cells11193006","article-title":"The effects of cannabidiol on aqueous humor outflow and trabecular meshwork cell signaling","volume":"11","author":"Aebersold","year":"2022","journal-title":"Cells."},{"key":"B291","doi-asserted-by":"publisher","first-page":"26555","DOI":"10.1073\/pnas.1911837116","article-title":"Increased stiffness and flow resistance of the inner wall of Schlemm's canal in glaucomatous human eyes","volume":"116","author":"Vahabikashi","year":"2019","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B292","doi-asserted-by":"publisher","first-page":"110","DOI":"10.21608\/ejomos.2021.57582.1006","article-title":"Rho-kinase inhibitors as a novel medication for glaucoma treatment \u2013 a review of the literature","volume":"1","author":"Ghanem","year":"2021","journal-title":"Egypt J Ophthalmol Mansoura Ophthalmic Cent."},{"key":"B293","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1016\/j.ymthe.2023.03.008","article-title":"Neuroserpin gene therapy inhibits retinal ganglion cell apoptosis and promotes functional preservation in glaucoma","volume":"31","author":"Chitranshi","year":"2023","journal-title":"Mol Ther J Am Soc Gene Ther."},{"key":"B294","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.3390\/ijms23073935","article-title":"The role of axonal transport in glaucoma","volume":"23","author":"Dias","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B295","doi-asserted-by":"publisher","first-page":"6262","DOI":"10.3390\/ijms21176262","article-title":"Neuroprotection of retinal ganglion cells with AAV2-BDNF pretreatment restoring normal TrkB receptor protein levels in glaucoma","volume":"21","author":"W\u00f3jcik-Gryciuk","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B296","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1089\/hum.2017.069","article-title":"Design of a novel gene therapy construct to achieve sustained brain-derived neurotrophic factor signaling in neurons","volume":"29","author":"Osborne","year":"2018","journal-title":"Hum Gene Ther."},{"key":"B297","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.ymthe.2022.11.018","article-title":"Vision protection and robust axon regeneration in glaucoma models by membrane-associated Trk receptors","volume":"31","author":"Nishijima","year":"2023","journal-title":"Mol Ther."},{"key":"B298","first-page":"409","article-title":"Tyrosine triple mutated AAV2-BDNF gene therapy in an inner retinal injury model induced by intravitreal injection of N\u2013methyl-D-aspartate (NMDA)","volume":"26","author":"Shiozawa","year":"2020","journal-title":"Mol Vis."},{"key":"B299","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1167\/iovs.08-3013","article-title":"Effect of CNTF on retinal ganglion cell survival in experimental glaucoma","volume":"50","author":"Pease","year":"2009","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B300","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-018-1049-0","article-title":"Novel engineered, membrane-localized variants of vascular endothelial growth factor (VEGF) protect retinal ganglion cells: a proof-of-concept study","volume":"9","author":"Shen","year":"2018","journal-title":"Cell Death Dis."},{"key":"B301","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-021-04068-x","article-title":"BCLXL gene therapy moderates neuropathology in the DBA\/2J mouse model of inherited glaucoma","volume":"12","author":"Donahue","year":"2021","journal-title":"Cell Death Dis."},{"key":"B302","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41434-021-00281-7","article-title":"XIAP gene therapy effects on retinal ganglion cell structure and function in a mouse model of glaucoma","volume":"29","author":"Visuvanathan","year":"2022","journal-title":"Gene Ther."},{"key":"B303","doi-asserted-by":"publisher","first-page":"4626","DOI":"10.4049\/jimmunol.1601488","article-title":"Overexpression of soluble fas ligand following adeno-associated virus gene therapy prevents retinal ganglion cell death in chronic and acute murine models of glaucoma","volume":"197","author":"Krishnan","year":"2016","journal-title":"J Immunol."},{"key":"B304","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.ymthe.2022.01.035","article-title":"NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function","volume":"30","author":"Fang","year":"2022","journal-title":"Mol Ther."},{"key":"B305","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12974-016-0499-5","article-title":"Virus-mediated EpoR76E gene therapy preserves vision in a glaucoma model by modulating neuroinflammation and decreasing oxidative stress","volume":"13","author":"Hines-Beard","year":"2016","journal-title":"J Neuroinflammation."},{"key":"B306","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1016\/j.cell.2021.06.031","article-title":"Preservation of vision after CaMKII-mediated protection of retinal ganglion cells","volume":"184","author":"Guo","year":"2021","journal-title":"Cell."},{"key":"B307","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1167\/iovs.63.2.5","article-title":"Neuroprotective gene therapy by overexpression of the transcription factor MAX in rat models of glaucomatous neurodegeneration","volume":"63","author":"Lani-Louzada","year":"2022","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B308","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.omtm.2017.04.003","article-title":"Spatially and temporally regulated NRF2 gene therapy using Mcp-1 promoter in retinal ganglion cell injury","volume":"5","author":"Fujita","year":"2017","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B309","doi-asserted-by":"publisher","first-page":"e8206849","DOI":"10.1155\/2020\/8206849","article-title":"Hyperbranched cationic glycogen derivative-mediated I\u03baB\u03b1 gene silencing regulates the uveoscleral outflow pathway in rats","volume":"2020","author":"Zeng","year":"2020","journal-title":"BioMed Res Int."},{"key":"B310","doi-asserted-by":"publisher","first-page":"6154","DOI":"10.7150\/thno.55472","article-title":"Inner retinal injury in experimental glaucoma is prevented upon AAV mediated Shp2 silencing in a caveolin dependent manner","volume":"11","author":"Abbasi","year":"2021","journal-title":"Theranostics."},{"key":"B311","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1089\/hum.2019.056","article-title":"Silencing of GAS5 alleviates glaucoma in rat models by reducing retinal ganglion cell apoptosis","volume":"30","author":"Zhou","year":"2019","journal-title":"Hum Gene Ther."},{"key":"B312","doi-asserted-by":"publisher","first-page":"613","DOI":"10.14348\/molcells.2014.0155","article-title":"Oncomodulin\/truncated protamine-mediated Nogo-66 receptor small interference RNA delivery promotes axon regeneration in retinal ganglion cells","volume":"37","author":"Cui","year":"2014","journal-title":"Mol Cells."},{"key":"B313","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/23808993.2020.1756770","article-title":"Personalized approaches for the management of glaucoma","volume":"5","author":"Balendra","year":"2020","journal-title":"Expert Rev Precis Med Drug Dev."},{"key":"B314","doi-asserted-by":"publisher","first-page":"e69882","DOI":"10.7759\/cureus.69882","article-title":"Secondary glaucoma following corneal transplantation: a comprehensive review of pathophysiology and therapeutic approaches","volume":"16","author":"Donthula","year":"2024","journal-title":"Cureus."},{"key":"B315","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.1442-9071.2011.02742.x","article-title":"Australian and New Zealand Registry of Advanced Glaucoma: methodology and recruitment","volume":"40","author":"Souzeau","year":"2012","journal-title":"Clin Experiment Ophthalmol."},{"key":"B316","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/bmjophth-2017-000131","article-title":"LncRNAs in genetic basis of glaucoma","volume":"3","author":"Ciss\u00e9","year":"2018","journal-title":"BMJ Open Ophthalmol."},{"key":"B317","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/jamaophthalmol.2024.0220","article-title":"The role of polygenic risk scores in glaucoma management","volume":"142","author":"Li","year":"2024","journal-title":"JAMA Ophthalmol."},{"key":"B318","doi-asserted-by":"publisher","first-page":"1157773","DOI":"10.3389\/fmed.2023.1157773","article-title":"Biochemical\u2013molecular\u2013genetic biomarkers in the tear film, aqueous humor, and blood of primary open-angle glaucoma patients","volume":"10","author":"Pinazo-Dur\u00e1n","year":"2023","journal-title":"Front Med."},{"key":"B319","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.3390\/life13071455","article-title":"New biomarker combination related to oxidative stress and inflammation in primary open-angle glaucoma","volume":"13","author":"Dammak","year":"2023","journal-title":"Life."},{"key":"B320","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41598-021-81048-3","article-title":"Aqueous autotaxin and TGF-\u03b2s are promising diagnostic biomarkers for distinguishing open-angle glaucoma subtypes","volume":"11","author":"Igarashi","year":"2021","journal-title":"Sci Rep."},{"key":"B321","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/aos.15808","article-title":"The use of benzalkonium chloride in topical glaucoma treatment: an investigation of the efficacy and safety of benzalkonium chloride-preservedintraocular pressure-lowering eye drops and their effect on conjunctival goblet cells","volume":"101","author":"Nagstrup","year":"2023","journal-title":"Acta Ophthalmol (Copenh)."},{"key":"B322","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40662-022-00298-y","article-title":"Nanoparticles for the treatment of glaucoma-associated neuroinflammation","volume":"9","author":"Lambuk","year":"2022","journal-title":"Eye Vis."},{"key":"B323","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.preteyeres.2011.11.002","article-title":"The molecular basis of retinal ganglion cell death in glaucoma","volume":"31","author":"Almasieh","year":"2012","journal-title":"Prog Retin Eye Res."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1527319\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T05:01:05Z","timestamp":1742965265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1527319\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":323,"alternative-id":["10.3389\/fmed.2025.1527319"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1527319","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"article-number":"1527319"}}